Neratinib Plus Chemotherapy Improved PFS in HER2+ Breast Cancer With CNS Involvement

Neratinib plus capecitabine improved progression-free survival and time to intervention for central nervous system disease in patients with previously treated HER2-positive metastatic breast cancer compared with lapatinib plus capecitabine, results from the phase 3 NALA trial show.

Read the full article here

Related Articles